| Chemical Name |
Canagliflozin Hemihydrate |
| CAS Number |
928672-86-0 |
| CAT Number |
RF-API22 |
| Stock Status |
In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula |
C24H27FO6S |
| Molecular Weight |
462.53 |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White Powder |
| Identification |
HPLC/NMR |
| Solubility |
Very Soluble in methanol; Soluble in ethanol, acetonitrile; Slightly soluble in water |
| Purity / Analysis Method |
≥99.0% (HPLC) |
| Individual Impurity |
≤0.10% |
| Total Impurities |
≤0.50% |
| Residual Solvents |
|
| Methanol |
≤3000ppm |
| Ethanol |
≤5000ppm |
| Acetonitrile |
≤400ppm |
| Dichloromethane |
≤600ppm |
| Ethyl Acetate |
≤5000ppm |
| THF |
≤720ppm |
| Toluene |
≤890ppm |
| Test Standard |
Chinese Pharmacopoeia (CP); Enterprise Standard |
| Usage |
Active Pharmaceutical Ingredient (API); SGLT-2 inhibitors Type 2 Diabetes |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Canagliflozin is a drug of the gliflozin class or subtype 2 sodium-glucose transport inhibitors (SGLT2) used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. In March 2013, canagliflozin became the first SGLT2 inhibitor to be approved in the United States.
Canagliflozin, to mention the advantage, this drug helps patients to reduce blood sugars without increasing the likelihood of gaining weight as long as a healthy, balanced diet is followed and regular exercise taken. In addition, Canagliflozin has a broad prospect due to its significant antiobesity effects and few hypoglycemic events.